Among 168,456 UK Biobank participants followed prospectively, those scoring ≥6 on the Dietary Index for Gut Microbiota (DI-GM) — a 12-item metric averaging foods and nutrients that support microbial diversity — showed a 22% lower hazard of metabolic dysfunction-associated steatotic liver disease (MASLD) compared to those scoring 0–3 (HR=0.78, 95% CI=0.68–0.90). Crucially, this protection persisted regardless of polygenic risk score for hepatic steatosis, and mediation analyses identified five significant pathways: phenotypic age acceleration, BMI, a metabolic score, an inflammatory score, and a plasma metabolomic signature derived via elastic net regression.
The finding matters because MASLD now affects roughly one-in-three adults globally and lacks approved pharmacotherapy for most patients, making diet the primary modifiable lever. What distinguishes this analysis from prior dietary-pattern studies is the explicit gut-microbiome framing and the plasma metabolome bridge — suggesting the liver benefit is partially encoded in measurable circulating metabolites, opening a route toward biomarker-based risk stratification. The genetic independence finding is particularly compelling: it implies dietary quality can partially override inherited hepatic fat deposition risk, a message with real clinical utility.
Limitations are real. UK Biobank is observational, predominantly white, and dietary data rely on self-report with known recall bias. DI-GM score thresholds are arbitrary. Causality remains unproven. Still, the scale, the mechanistic mediation framework, and genetic interaction testing elevate this beyond incremental — it is methodologically substantive and practically actionable for liver disease prevention strategies.
